You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
勵晶太平洋(00575.HK):合作商江蘇萬邦醫藥新藥申請獲藥監局首輪詢問 對年底獲批感樂觀
勵晶太平洋(00575.HK)公布,其商業戰略合作夥伴江蘇萬邦醫藥,為復星醫藥(02196.HK)正在推進SenstendTM於國家藥品監督管理局的新藥申請,已收到藥監局就新藥申請檔案的第一輪詢問,並已及時提交全面回應。蘇萬邦醫藥對於在2025年底前獲得新藥申請批准,並於2026年第一季度開始首次商業化上市仍持樂觀態度。 倘國家藥品監督管理局授予SenstendTM進口許可證,則江蘇萬邦醫藥將須向集團支付500萬美元(或約3,900萬港元)(扣除中國預扣稅前)。此外,待SenstendTM於中國進行首次商業銷售後,江蘇萬邦醫藥將須向集團支付200萬美元(或約1,560萬港元)(扣除中國預扣稅前)。再者,公司在今年3月之公佈所披露江蘇萬邦醫藥應就商業里程碑及特許權使用費向集團支付其他重大付款。 勵晶太平洋續指,公司之一家全資附屬公司「Deep Longevity」於本年度上半年在新客戶拓展方面持續取得進展,值得注意的新客戶包括香港的仁山醫療及印度的Holistica World。 公告指,Deep Longevity致力於最大的長壽市場美國推出老化時鐘,並委聘一名美國總裁領導該市場的拓展工作,相信這將推動業務增長。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account